

Creatinine PAP FS*

Diagnostic reagent for quantitative in vitro determination of creatinine in serum, plasma or urine on BioMaiesty JCA-BM6010/C

Order information

| Cat. No. | Test | s | |
|------------------|------|-----|-----------|
| 1 1759 99 10 963 | R1 | 4 x | 450 tests |
| | R2 | 3 x | 600 tests |
| 1 1759 99 10 962 | R1 | 6 x | 340 tests |
| | R2 | 6 x | 340 tests |

Method

Enzymatic colorimetric test

Principle

Creatinine is determined by the following reaction:

The absorbance of the produced red dye at 545 nm is proportional to the creatinine concentration in the sample.

Reagents

Components and Concentrations

| R1: | Goods buffer Creatinase Sarcosine oxidase | pH 8.1 | 25 mmol/L ≥ 30 kU/L ≥ 10 kU/L |
|-----|--|--------------------------------|---|
| R2: | Ascorbate oxidase Catalase HTIB (3-Hydroxy 2,4,6-t Goods buffer | riiodo benzoic acid) pH 8.1 | ≥ 2.5 kU/L ≥ 350 kU/L 2.3 mmol/L 25 mmol/L |
| | Creatininase Peroxidase 4-Aminoantipyrine (4-AAPOtassium hexacyanofe | | ≥ 150 kU/L ≥ 50 kU/L 2 mmol/L 0.18 mmol/L |

Storage Instructions and Reagent Stability

The reagents are stable up to the end of the indicated month of expiry, if stored at $2-8^{\circ}$ C, protected from light and contamination is avoided. Do not freeze the reagents!

Warnings and Precautions

- Reagent 2 contains sodium azide (0.95 g/L) as preservative.
 Do not swallow! Avoid contact with skin and mucous membranes.
- 2. High homogentisic acid concentrations in urine samples lead to false results.
- In very rare cases, samples of patients with gammopathy might give falsified results [9].
- N-acetylcysteine (NAC), acetaminophen, metamizole and phenindione medication leads to falsely low, eltrombopag medication to falsely low or high results in patient samples.
- Please refer to the safety data sheets and take the necessary precautions for the use of laboratory reagents. For diagnostic purposes, the results should always be assessed with the patient's medical history, clinical examinations and other findings.
- 6. For professional use only!

Waste Management

Please refer to local legal requirements.

Reagent Preparation

The reagents are ready to use. The bottles are placed directly into the reagent trays.

Specimen

Serum, heparin plasma or urine

| Stability in ser | um and plas | ma [1]: |
|-------------------|-------------|-----------|
| 7 days | at | 4 – 25°C |
| 3 months | at | –20°C |
| Stability in urin | ne [1]: | |
| 2 days | at | 20 - 25°C |
| 6 days | at | 4 – 8°C |
| 6 months | at | –20°C |

Freeze only once! Discard contaminated specimens. TruLab Urine controls must be prediluted the same way as patient samples.

Calibrators and Controls

For calibration the DiaSys TruCal U calibrator is recommended. The calibrator values have been made traceable to NIST (National Institute for Standardization) Standard Reference Material SRM 967 using level 1 and 2 and, therefore, to GC-IDMS (gas chromatography-isotope dilution mass spectrometry). For internal quality control DiaSys TruLab N, TruLab P and TruLab Urine controls should be assayed. Each laboratory should establish corrective action in case of deviations in control recovery.

| | | | , |
|----------------------|------------------|----|---------|
| | Cat. No. | K | it size |
| TruCal U | 5 9100 99 10 063 | 20 | x 3 mL |
| | 5 9100 99 10 064 | 6 | x 3 mL |
| TruLab N | 5 9000 99 10 062 | 20 | x 5 mL |
| | 5 9000 99 10 061 | 6 | x 5 mL |
| TruLab P | 5 9050 99 10 062 | 20 | x 5 mL |
| | 5 9050 99 10 061 | 6 | x 5 mL |
| TruLab Urine Level 1 | 5 9170 99 10 062 | 20 | x 5 mL |
| | 5 9170 99 10 061 | 6 | x 5 mL |
| TruLab Urine Level 2 | 5 9180 99 10 062 | 20 | x 5 mL |
| | 5 9180 99 10 061 | 6 | x 5 mL |

Performance Characteristics

| Measuring range up to 30 mg/dL (2800 µmol/L) creatinine (in case of higher concentrations re-measure samples after manual dilution with NaCl solution (9 g/L) or use rerun function) | | |
|--|--|--|
| Limit of detection** 0.02 mg/dL (1.59 µmol/L) creatinine | | |
| On-board stability 6 weeks | | |
| Calibration stability 6 weeks | | |

| Interferences < 10% by |
|--|
| Ascorbate up to 27 mg/dL |
| Conjugated Bilirubin up to 18 mg/dL |
| Unconjugated Bilirubin up to 24 mg/dL |
| Hemoglobin up to 500 mg/dL |
| Creatine up to 40 mg/dL |
| Lipemia (triglycerides) up to 1700 mg/dL |
| Proline up to 12 mg/dL |
| For further information on interfering substances refer to Young DS [8]. |

| Precision (Serum/plasma) | | | |
|------------------------------|----------|----------|----------|
| Within run (n=20) | Sample 1 | Sample 2 | Sample 3 |
| Mean [mg/dL] | 0.65 | 1.24 | 7.13 |
| Mean [µmol/L] | 57.8 | 109 | 630 |
| Coefficient of variation [%] | 0.94 | 1.32 | 0.93 |
| Between run (n=20) | Sample 1 | Sample 2 | Sample 3 |
| Mean [mg/dL] | 0.65 | 1.85 | 6.44 |
| Mean [µmol/L] | 57.4 | 164 | 569 |
| Coefficient of variation [%] | 1.67 | 1.51 | 1.77 |

| Method comparison (Serum/plasma; n=100) | | |
|---|--------------------------|--|
| Test x | Competitor Creatinine | |
| Test y | DiaSys Creatinine PAP FS | |
| Slope | 0.993 | |
| Intercept | 0.04 mg/dL (3.42 µmol/L) | |
| Coefficient of correlation | 0.999 | |

Reagent Information * fluid stable



| Precision (Urine) | | | |
|------------------------------|----------|----------|----------|
| Within run (n=20) | Sample 1 | Sample 2 | Sample 3 |
| Mean [mg/dL] | 51.3 | 59.2 | 114 |
| Mean [mmol/L] | 4.54 | 5.24 | 10.1 |
| Coefficient of variation [%] | 1.29 | 1.42 | 1.36 |
| Between run (n=20) | Sample 1 | Sample 2 | Sample 3 |
| Mean [mg/dL] | 50.6 | 60.2 | 115 |
| Mean [mmol/L] | 4.47 | 5.32 | 10.1 |
| Coefficient of variation [%] | 2.31 | 1.79 | 1.50 |

| Method comparison (Urine; n=100) | | |
|----------------------------------|---------------------------|--|
| Test x | Competitor Creatinine | |
| Test y | DiaSys Creatinine PAP FS | |
| Slope | 1.02 | |
| Intercept | 0.69 mg/dL (0.061 mmol/L) | |
| Coefficient of correlation | 0.998 | |

lowest measurable concentration which can be distinguished from zero mean + 3 SD (n=20) of an analyte free specimen

Creatinine [mg/dL] x 88.4 = Creatinine [µmol/L] Creatinine [mg/dL] x 0.0884 = Creatinine [mmol/L]

Calculation

Creatinine-Clearance [mL/min/1.73 m²] [2]

mg Creatinine / 100 mL Urine \times mL Urine mg Creatinine / 100 mL Serum × min Urine collection time

The calculated creatinine clearance refers to the average body surface of an adult (1.73 m²).

Reference Range

Serum/Plasma

| | mg/dL | μmol/L |
|---|--|--|
| Adults [4] Women Men | 0.51 - 0.95 0.67 - 1.17 | 45 – 84 59 – 104 |
| Children [5] 0 - 7 days 1 week - 1 month 1 - 6 month(s) 7 - 12 months | 0.6 - 1.1 0.3 - 0.7 0.2 - 0.4 0.2 - 0.4 | 53 – 97 27 – 62 18 – 35 18 – 35 |
| 1 – 18 year(s) Morning urine [4] Women Men | 0.2 - 0.7 29 - 226 40 - 278 | 18 – 62 2.55 – 20.0 3.54 – 24.6 |

24h urine [2]

Women 720 - 1510 mg/24h 6 - 13 mmol/24h 980 - 2200 mg/24h 9 - 19 mmol/24h

Albumin/creatinine ratio (early morning urine) [10]:

< 30 mg/g Creatinine

Creatinine clearance [2]

66.3 - 143 mL/min/1.73 m²

Each laboratory should check if the reference ranges are transferable to its own patient population and determine own reference ranges if necessary.

Literature

- Guder WG, Zawta B. Recommendations of the Working group on Preanalytical Quality of the German Society for Clinical Chemistry and the German Society for Laboratory Medicine: The Quality of Diagnostic Samples. 1st ed Darmstadt: GIT Verlag 2001; p. 24-5, 50-1
- Junge W, Wilke B, Halabi A, Klein G. Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffé method. Clin Chim Acta 2004; 344: 137-148
- Levey AS, Coresh J, Greene T, Marsh J et al: Expressing the Modification of Diet in Renal Disease Study Equation for Estimating
- Glomerular Filtration Rate with Standardized Serum Creatinine Values. Clin Chem 2007; 53 (4): 766-72.

 Mazzachi BC, Peake M, Erhardt V. Reference range and method comparison for enzymatic and Jaffé Creatinine assays in plasma and serum and early morning urine. Clin Lab 2000; 46: 53-5.
- Schlebusch Soldin SJ, HicksJM. Pediatric reference ranges. Washington: AACC Press, 1995:50.
- Newman DJ, Price CP. Renal function and nitrogen metabolites. In: Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry.
- 3rd ed. Philadelphia: W.B Saunders Company; 1999. p. 1204–1270. Thomas L. Clinical Laboratory Diagnostics. 1st ed. Frankfurt: TH-Books
- Verlagsgesellschaft; 1998. p. 366-74. Young DS. Effects of Drugs on Clinical Laboratory Tests. 5th ed. Volume 1 and 2. Washington, DC: The American Association for Clinical Chemistry Press 2000.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. ClinChemLabMed 2007;45(9):1240-1243.
- Dati F, Metzmann E. Proteins-Laboratory testing and clinical use. 1st ed. Holzheim: DiaSys Diagnostic Systems; 2005: p. 93.

Manufacturer



DiaSys Diagnostic Systems GmbH Alte Strasse 9 65558 Holzheim Germany



Creatinine PAP FS

Chemistry code 10 175

Application for serum, plasma and urine samples

This application was set up and evaluated by DiaSys. It is based on the standard equipment at that time and does not apply to any equipment modifications undertaken by unqualified personnel.

| Analytical Conditions | | |
|-----------------------|------|--|
| R1 volume | 80 | |
| R2e volume | 0 | |
| R2 volume | 40 | |
| R1 diluent vol | 0 | |
| R2e diluent vol | 0 | |
| R2 diluent vol | 0 | |
| Sample vol (S) | 2 | |
| Sample vol (U) | 2 | |
| Reagent 1 mix | weak | |
| Reagent 2e mix | weak | |
| Reagent 2 mix | weak | |
| Reaction time | 10 | |

| Sub-analy. Conditions | | |
|-----------------------|-------|--|
| Name | CREAP | |
| Digits | 2 | |
| M-wave L. | 545 | |
| S-wave.L | 694 | |
| Analy.mthd. | EPA | |
| Calc.mthd. | STD | |
| Qualit. judge | No | |

| Analysis Test Condition Setting (M) | | | |
|-------------------------------------|--------|----------|--|
| Sample Type | Serum | Urine | |
| Reac. sample vol. | 2 | 2 | |
| Diluent method | No dil | With dil | |
| Undil. sample vol. | 0 | 5 | |
| Diluent volume | 0 | 45 | |
| Diluent position | 0 | 0 | |

entered by user

| Endpoint method | | |
|-----------------|--------|--|
| Re.absorb (u) | 9.999 | |
| Re. Absorb (d) | -9.999 | |

| Calculation Method Setting | | |
|----------------------------|-------|--|
| M-DET.P.I | 0 | |
| M-DET.P.m | 41 | |
| M-DET.P.n | 42 | |
| S-DET.P.p | 17 | |
| S-DET.P.r | 18 | |
| Check D.P.I. | 0 | |
| Limit value | 0.003 | |
| Variance | 10 | |
| Reac.type | Inc | |

| Reaction Rate Method | | |
|----------------------|--------|--|
| Cycle | 2 | |
| Factor | 2 | |
| E2 corre | Not Do | |
| Blank (u) | 9.999 | |
| Blank (d) | -9.999 | |
| Sample (u) | 9.999 | |
| Sample (d) | -9.999 | |

| Standards Setting | |
|-------------------|--------|
| FV | # |
| BLK H | 9.999 |
| BLK L | -9.999 |
| STD H | 9.999 |
| STD L | -9.999 |